Putaminal dopamine modulates movement motivation in Parkinson’s disease
Objective: To investigate the quantitative effect of dopamine depletion on the motivation of motor effort in Parkinson’s disease. Background: The relative inability to produce effortful…Dopaminergic alterations in patients with Alzheimer’s disease
Objective: The objective of this study was to conduct a meta-analysis to determine the pooled mean difference (MD) in dopaminergic measures between Alzheimer’s disease and…Criteria Defining Chronic Pain Associated with Parkinson Disease
Objective: To assess the factors defining the association of chronic pain (>3 months) with PD. Background: Non-motor symptoms can be often associated with Parkinson disease…Comorbidity of schizophrenia and Parkinson’s disease: a clinical case report
Objective: To describe the case of a patient with paranoid schizophrenia followed by the onset of the Parkinson’s disease at the 44-year age Background: Currently…Characterizing Dopaminergic Correlates of Depression in Parkinson’s Disease: The PPMI Cohort
Objective: We explored the association between cerebrospinal fluid (CSF) dopamine metabolites and transporter denervation in the development of depression in Parkinson Disease (PD). Background: Depression…Pharmacological neuromodulation with intracerebroventricular administration of anaerobic dopamine for Parkinson’s disease
Objective: To assess the continuous intracerebroventricular (i.c.v.) of A-dopamine in patients with a telemetry-controlled intra-abdominal pump system connected to a subcutaneous catheter implanted through the…The Effect of Modulating Alpha-synuclein Aggregation on Clinical Outcome in the Presence of Standard-of-care Dopaminergic Therapy in Parkinson’s Disease. A Quantitative Systems Pharmacology Approach.
Objective: Understanding the biological link between alpha-synuclein biomarker changes and clinical outcome using computer simulation. Background: A number of disease modifying therapeutic interventions focused on…Formulations and Assessments of Intra-nasal noses to brain curcumin delivery using reversible nanoparticles for Parkinsonism treatment: A Preclinical Approach
Objective: Parkinson's disease (PD) is a prevalent neurological illness that is typified by bradykinesia, postural instability, tremor, and stiffness. An increasing body of research suggests…Spray with Nasal Mucoadhesive Microspheres for Treating Parkinsonism.
Objective: Although levodopa is the preferred medication for treating Parkinson's disease, it has a very poor brain absorption and limited oral bioavailability. The goal of…A Quantitative Investigation has Revealed Nifedipine as a Possible Pharmacological Modulator in Parkinson’s Disease
Objective: Parkinson's Disease (PD) is strongly linked to atypical electrical firing patterns in the neuronal cells of the globus pallidus externus (GPe), hence highlighting the…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 26
- Next Page »